GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: Example 16 [WO2008036579A1] | LY-2371712 | LY2371712 | SPR-001 | SPR001
Compound class:
Synthetic organic
Comment: Tildacerfont is a corticotropin-releasing factor (CRF) receptor antagonist. It is proposed to reduce the overproduction of androgens in people with congenital adrenal hyperplasia (CAH), by targeting CRF1 receptor-mediated ACTH secretion. It was designed to address the lipophilicity and associated toxicity liability observed for earlier molecules.
The IUPAC provided for tildacerfont's INN record generates the molecule with the chemical structure shown here and this is same the structure that is associated with CAS registry ID 1014983-00-6 (also provided in the INN record). This has a slightly different structure on the thiazole ring compared to PubChem's entry for tildacerfont (CID 134694266). ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chen Z, Hamdouchi CH, Hembre EJ, Hipskind PA, Myers JK, Takakuwa T, Toth JL. (2008)
Thiazole pyrazolopyrimidines as crf1 receptor antagonists. Patent number: WO2008036579A1. Assignee: Eli Lilly And Company. Priority date: 17/09/2007. Publication date: 27/03/2008. |
2. Sarafoglou K, Barnes CN, Huang M, Imel EA, Madu IJ, Merke DP, Moriarty D, Nakhle S, Newfield RS, Vogiatzi MG et al.. (2021)
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. J Clin Endocrinol Metab, 106 (11): e4666-e4679. [PMID:34146101] |